Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Importance Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. Objective To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. Design, Setting, and Participants This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. Exposures Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. Main Outcomes and Measures Overall survival time. Results The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. Conclusions and Relevance This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

[1]  Evaluation of tumor infiltrating lymphocytes in breast cancer , 2018 .

[2]  T. Sellers,et al.  Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[3]  Kconfab Investigators,et al.  Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer , 2017 .

[4]  J. Schildkraut,et al.  Ovarian cancer epidemiology in the era of collaborative team science , 2017, Cancer Causes & Control.

[5]  J. Schorge,et al.  Trends in the Use of Neoadjuvant Chemotherapy for Advanced Ovarian Cancer in the United States , 2017 .

[6]  C. Genestie,et al.  Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Lara E Sucheston-Campbell,et al.  Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer , 2017, Nature Genetics.

[8]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[9]  Carsten Denkert,et al.  Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group , 2016, Modern Pathology.

[10]  D. Tritchler,et al.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Köbel,et al.  Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype‐specific Lynch syndrome screening in ovarian carcinomas , 2016, Histopathology.

[12]  S. Leung,et al.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[14]  A. Reuss,et al.  Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.

[15]  Preetha Ramalingam,et al.  Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer. , 2016, Oncology.

[16]  Lauren L. Ritterhouse,et al.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.

[17]  B. Nelson,et al.  Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer , 2016, Clinical Cancer Research.

[18]  S. Mabuchi,et al.  Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives , 2016, Journal of gynecologic oncology.

[19]  Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Gourley,et al.  Low-grade epithelial ovarian cancer: a number of distinct clinical entities? , 2015, Current opinion in oncology.

[22]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[23]  A. Whittemore,et al.  Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer , 2014, Clinical Cancer Research.

[24]  M. Beckmann,et al.  Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study , 2014, British Journal of Cancer.

[25]  J. George,et al.  Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver , 2014, Clinical Cancer Research.

[26]  E. Goode,et al.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.

[27]  M. Köbel,et al.  Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry , 2014, Histopathology.

[28]  L. Meng,et al.  The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis , 2014, PloS one.

[29]  R. Kurman Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Claudia C. Preston,et al.  The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer , 2013, PloS one.

[31]  A. Whittemore,et al.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.

[32]  R. Bristow,et al.  Survival in Women With Grade 1 Serous Ovarian Carcinoma , 2013, Obstetrics and gynecology.

[33]  Francesmary Modugno,et al.  Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[34]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[35]  Peter Cresswell,et al.  Pathways of antigen processing. , 2013, Annual review of immunology.

[36]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Berkowitz,et al.  Endometriosis-Associated Ovarian Cancer: A Review of Pathogenesis , 2013, International journal of molecular sciences.

[38]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[39]  Carsten Denkert,et al.  Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.

[40]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[41]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[42]  G. Coukos,et al.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.

[43]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[44]  M. Köbel,et al.  Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. , 2011, The Lancet. Oncology.

[45]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[46]  Wendy Frankel,et al.  Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. , 2009, Archives of pathology & laboratory medicine.

[47]  Matt van de Rijn,et al.  Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.

[48]  R. Berkowitz,et al.  Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer , 2008, Clinical Cancer Research.

[49]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[50]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[51]  Soldano Ferrone,et al.  HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma , 2008, Clinical Cancer Research.

[52]  I. Šteiner,et al.  Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. , 2008, Gynecologic oncology.

[53]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[55]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[56]  Paul H. C. Eilers,et al.  Flexible smoothing with B-splines and penalties , 1996 .